Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/eji.202048693 http://scihub22266oqcxt.onion/10.1002/eji.202048693 32438473!7280664!32438473     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Immunol 2020 ; 50 (7): 932-938 Nephropedia Template TP {{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity |pdf=|usr=}}{{32438473}} gab.com Text Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity JO: Eur J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32438473 #FOAvip The recent outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses an enormous threat to global public health and economies. Human coronaviruses normally cause no or mild respiratory disease but in the past two decades, potentially fatal coronavirus infections have emerged, causing respiratory tract illnesses such as pneumonia and bronchitis. These include severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV), and recently the SARS-CoV-2 coronavirus outbreak that emerged in Wuhan, China, in December 2019. Currently, most COVID-19 patients receive traditional supportive care including breathing assistance. To halt the ongoing spread of the pandemic SARS-CoV-2 coronavirus and rescue individual patients, established drugs and new therapies are under evaluation. Since it will be some time until a safe and effective vaccine will be available, the immediate priority is to harness innate immunity to accelerate early antiviral immune responses. Second, since excessive inflammation is a major cause of pathology, targeted anti-inflammatory responses are being evaluated to reduce inflammation-induced damage to the respiratory tract and cytokine storms. Here, we highlight prominent immunotherapies at various stages of development that aim for augmented anti-coronavirus immunity and reduction of pathological inflammation. Twit Text FOAVip Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity ????Eur J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32438473 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32438473 #FOAvip English Wikipedia <ref>{{Cite pmid|32438473}}</ref> Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity #MMPMID32438473 Schijns V; Lavelle EC Eur J Immunol 2020[Jul]; 50 (7): 932-938 PMID32438473show ga The recent outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses an enormous threat to global public health and economies. Human coronaviruses normally cause no or mild respiratory disease but in the past two decades, potentially fatal coronavirus infections have emerged, causing respiratory tract illnesses such as pneumonia and bronchitis. These include severe acute respiratory syndrome coronavirus (SARS-CoV), followed by the Middle East respiratory syndrome coronavirus (MERS-CoV), and recently the SARS-CoV-2 coronavirus outbreak that emerged in Wuhan, China, in December 2019. Currently, most COVID-19 patients receive traditional supportive care including breathing assistance. To halt the ongoing spread of the pandemic SARS-CoV-2 coronavirus and rescue individual patients, established drugs and new therapies are under evaluation. Since it will be some time until a safe and effective vaccine will be available, the immediate priority is to harness innate immunity to accelerate early antiviral immune responses. Second, since excessive inflammation is a major cause of pathology, targeted anti-inflammatory responses are being evaluated to reduce inflammation-induced damage to the respiratory tract and cytokine storms. Here, we highlight prominent immunotherapies at various stages of development that aim for augmented anti-coronavirus immunity and reduction of pathological inflammation. |Animals[MESH] |Anti-Inflammatory Agents/adverse effects/*therapeutic use[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |Betacoronavirus/physiology[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/*drug therapy/*immunology/pathology/prevention & control/therapy[MESH] |Humans[MESH] |Immunity, Innate/*drug effects[MESH] |Immunization, Passive[MESH] |Immunomodulation[MESH] |Immunotherapy/*methods[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/*drug therapy/*immunology/pathology/prevention & control[MESH]Prevention and treatment of COVID-19 disease by controlled modulation (epmc).pdf DeepDyve Pubget Overpricing